How to protect the kidney in diabetic patients: With special reference to IDDM

Diabetes

Volumn 46, Issue SUPPL. 2, 1997, Pages

  Mogensen, C E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; COUGHING; DIABETIC NEPHROPATHY; DRUG MIXTURE; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RESTRICTION;

EID: 0030884023     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.s104     Document Type: Conference Paper

References (60)

1. Mogensen CE: Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 235:297-316, 1994
2. Mogensen CE: Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests. In The, Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Mogensen CE, Ed. London, Kluwer, 1996, p. 11-22
3. Parving H-H, Rossing P, Hommel E, Smidt UM: Angiotensin-converting enzyme-inhibition in diabetic nephropathy: 10 years experience. Am J Kidney Dis 26:99-107, 1995
4. Mogensen CE, Østerby R, Hansen KW, Damsgaard EM: Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 15:1192-1204, 1992
5. Ferrannini E: The metabolic syndrome. In Target Organ Damage in the Mature Hypertensive. Mogensen CE, Ed. London, Science, 1993, p. 2.31-2.49
6. Parving H-H, Rossing P: The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 3:292-300, 1994
7. Mogensen CE: Angiotensin converting enzyme inhibitors and diabetic nephropathy (Editorial). Br Med J 304;227-228, 1992
8. Mogensen CE, Hansen KW, Nielsen S, Mau Pedersen M, Rehling M, Schmitz A: Monitoring diabetic nephropathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease: reproducibility, progression, and efficacy of antihypertensive intervention. Am J Kidney Dis 22:174-187, 1993
9. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD: The effect of angiotensin-converting-enzyme inhibition on nephropathy. N Engl J Med 329:1456-1462, 1993
10. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T: Improved survival in patients with diabetic nephropathy. Diabetologia 32:884-886, 1989
11. Mogensen CE: Glomerular hyperfiltration in human diabetes. Diabetes Care 17:770-775, 1994
12. Toeller M, Klischan A, Heitkamp G, Schumacher W, Milne R, Buyken A, Karamanos B, Gries FA, the EURODIAB IDDM Complications Study Group: Nutritional intake of 2968 IDDM patients from 30 centres in Europe. Diabetologia 39:929-939, 1996
13. Krolewski AS, Laffel LMB, Krolpwski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332:1251-1255, 1995
14. Østerby R: Microalbuminuria in diabetes mellitus: is there a structural basis? (Editorial). Nephrol Dial Transplant 10:12-14, 1995
15. Schmitz A: Renal function changes in middle-aged and elderly Caucasian type 2 (non-insulin-dependent) diabetic patients: a review. Diabetologia 36:985-992, 1993
16. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
17. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T: Effect of improved metabolic control loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34:164-170, 1991
18. Microalbuminuria Captopril Study Group (Barnes DJ, Cooper M, Gans DJ, Laffel L, Mogensen CE, Viberti GC): Captopril reduces the risk of nephropathy in insulin-dependent diabetic patients with microalbuminuria. Diabetologia 39:587-593, 1996
19. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 156:286-289, 1996
20. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 36:383-388, 1976
21. Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516, 1994
22. Parving H-H, Smidt UM, Andersen AE, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet i:1175-1179, 1983
23. Mogensen CE: Angiotensin converting enzyme inhibitors and diabetic nephropathy: their effects on proteinuria may be independent of their effects on blood pressure (Editorial). Br Med J 304:327-328, 1992
24. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294:1443-1447, 1987
25. Björck S, Mulec H, Jonnsen SA, Nordén G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304:339-343, 1992
26. Gall M-A, Nielsen FS, Smidt UM, Parving H-H: The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36:1071-1078, 1993
27. Dullaart RPF, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ: Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16:483-492, 1993
28. Walker JD: Non-glycaemic intervention in diabetic nephropathy: the role of dietary protein intake. In The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Mogensen CE, Ed. London, Kluwer, 1996, p. 405-414
29. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324:78-84, 1991
30. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, for the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
31. Nyberg G, Nordén G, Attman P-O, Aurell M, Uddebom G, Lenner RA, Isaksson B: Diabetic nephropathy: is dietary protein harmful? J Diabetic Complications 1:37-40, 1987
32. Cortes P, Riser BL: The nature of the glomerulus: pressure-induced and metabolic aberrations. In The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Mogensen CE, Ed. London, Kluwer, 1996, p. 1-10
33. Mau Pedersen M: Early renal hyperfunction and hypertrophy in IDDM patients including comments on early intervention. In The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Mogensen CE, Ed. London, Kluwer, 1996, p. 341-350
34. Vlassara H, Bucala R: Advanced glycation and diabetes complications: an update. In The Diabetes Annual/9. Marshall SM, Home PD, Rizza RA, Eds. Amsterdam, Elsevier, 1995, p. 227-244
35. Friedman EA: Will pimagidine improve survival of diabetics on dialysis? Nephrol Dial Transplant 11:1524-1527, 1996
36. Kofoed-Enevoldsen: The Steno hypothesis and glomerular basement mem-brane biochemistry in diabetic nephropathy. In The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Mogensen CE, Ed. London, Kluwer, 1996, p. 235-244
37. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
38. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728-731, 1996
39. Drickanier K: Breaking the curse of the AGEs. Nature 382:211-212, 1996
40. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278, 1996
41. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 93:3902-3907, 1996
42. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Deleterious effect of a deletion polymorphism in angiotensin-converting enzyme gene on progression of diabetic nephropathy during angiotensin-converting enzyme inhibition. BMJ 313:591-594, 1996
43. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney 25:107-112, 1995
44. Mogeasen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. In The Kidney and Hypertension in Diabetes Mellitus. 3rd ed. Mogensen CE, Ed. London, Kluwer, 1994, p. 539-549
45. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 17:1357-1361, 1994
46. Jerums G, Cooper M, Gilbert R, O'Brien R, Taft J: Microalbuminuria in diabetes. Med J Aust 161:265-268, 1994
47. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjœr H, Frøland A, Hansen KW, Nielsen S, Mau Pedersen M: Microalbuminuria and potential confounders: a review and some observations on variability of urinary albumin excretion. Diabetes Care 18:572-581, 1995
48. Poulsen PL, Mogensen CE: Evaluation of a new semiquantitative stix for microalbuminuria Diabetes Care 18:732-733, 1995
49. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
50. Mogensen CE: Diabetic renal disease: the quest for normotension - and beyond. Diabetic Med 12:756-769, 1995
51. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
52. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 285:685-688, 1982
53. Parving H-H, Andersen AR, Schmidt UM, Christiansen JS, Oxenboll B, Svendsen PA: Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes 32 (Suppl. 2):83-87, 1983
54. Nyberg G, Blohmé G, Nordén G: Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30:82-86, 1987
55. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293:471-474, 1986
56. Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, Knaus V: A randomized, doubleblind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20:443-457, 1992
57. Elving LD, Wetzels JFM, van Lier HJJ, de Nobel E, Berden JHM: Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy: results of a 2-year prospective, randomized study. Diabetologia 37:604-609, 1994
58. Parving H-H, Rossing R, Hommel E, Smidt UM: Renal protective effects of captopril and metoprolol in diabetic nephropathy (Abstract). J Am Soc Nephrol 3:337, 1992
59. Wang PH: When should ACE-inhibitors be given to normotensive patients with IDDM? Lancet 349:1782-1783, 1997
60. The EUCLID Study Group: The effect of Lisinopril on retinopathy in people with IDDM (Abstract). Diabetologia 40 (Suppl. 1):A500, 1997